CIITA and neoplasm: Based on this evidence, our approach to stimulate the complex mechanism of anti-tumor immunity involves the modification of the tumor cells through genetic transfer of the MHC class II transactivator, also designated CIITA (19), the crucial physiological activator of MHC class II gene expression discovered in our laboratory (20–22).